EN DE
STOCK COMPARISON

Shandong Keyuan Pharmaceutical Co. Ltd. A vs Eli Lilly and: Fair Value & Quality

Both stocks run through our valuation models. Here is how Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) and Eli Lilly and (LLY) compare, as of Aug 14, 2026.

As of Aug 14, 2026, Fair Value Calculator sees Shandong Keyuan Pharmaceutical Co. Ltd. A as the less overvalued of the two: Shandong Keyuan Pharmaceutical Co. Ltd. A trades at ¥44.66 versus a fair value of ¥22.62 (-49%), while Eli Lilly and trades at $1,209 versus $389 (-68%).
Shandong Keyuan Pharmaceutical Co. Ltd. A
301281.SHE · CNY · Health Care
-49%
upside to fair value
overvalued
Price¥44.66
Fair Value¥22.62
Quality36/100
Eli Lilly and
LLY · USD · Health Care
-68%
upside to fair value
overvalued
Price$1,209
Fair Value$389
Quality69/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Shandong Keyuan Pharmaceutical Co. Ltd. AEli Lilly and
Valuation
212.7×P/E (TTM)42.2×
12.34×P/S (TTM)14.67×
4.08×P/B39.94×
66.0×EV/EBITDA30.2×
PEG1.54×
0.1%Dividend yield0.5%
¥0.05Dividend per share$6.23
Profitability
5%Net margin35%
20%Operating margin49%
2%Return on equity107%
1%Return on assets21%
Growth
45%Revenue growth (YoY)56%
-3.5%Avg. growth/yr (3Y)31.7%
Avg. growth/yr (5Y)21.6%
Balance & size
0.08×Debt / equity1.54×
$820MMarket cap$1.1T
weakGrowth qualitymixed

Eli Lilly and leads: 3 to 9 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Shandong Keyuan Pharmaceutical Co. Ltd. Aof which business quality 41 · market factors 62 Eli Lilly andof which business quality 65 · market factors 83
ProfitabilityMargins and returns on capital today
20
85
Quality GrowthAre margins and returns improving?
35
86
CashflowEarnings quality: real cash, not paper profit
36
51
Fin. StrengthBalance sheet, leverage, solvency risk
93
53
InvestmentDisciplined investing over empire-building
0
15
Low VolatilityCalm price path (market factor)
51
77
MomentumPrice trend over the last 3–12 months (market factor)
71
79
52W MomentumDistance to the 52-week high (market factor)
60
97
Net IssuanceBuybacks instead of dilution
40
93

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Shandong Keyuan Pharmaceutical Co. Ltd. A

Earnings-Based¥3.49
Multiples¥5.50
Asset-Based¥8.39
Economic Profit¥6.77
Growth Earnings¥2.54

12 of 12 models see the stock below the current price.

Eli Lilly and

DCF Models$334
Earnings-Based$239
Dividend Discount$115
Multiples$358
Asset-Based$19.94
Growth DCF$187
Economic Profit$347
Growth Earnings$375

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Shandong Keyuan Pharmaceutical Co. Ltd. A
Bear ¥16.96Fair Value ¥22.62Bull ¥28.27
¥44.66 = current price (white tick)
Eli Lilly and
Bear $216Fair Value $389Bull $582
$1,209 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Shandong Keyuan Pharmaceutical Co. Ltd. A · Health Care

Quality score36 · bottom 25%
Fair value upside-49% · below median

Eli Lilly and · Health Care

Quality score69 · Top 25%
Fair value upside-68% · bottom 25%

Bottom line

As of Aug 14, 2026, Fair Value Calculator sees Shandong Keyuan Pharmaceutical Co. Ltd. A as the less overvalued of the two: Shandong Keyuan Pharmaceutical Co. Ltd. A trades at ¥44.66 versus a fair value of ¥22.62 (-49%), while Eli Lilly and trades at $1,209 versus $389 (-68%).

Eli Lilly and has the higher quality score (69/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.